Barinthus Bio Q3 net loss narrows to $8.1M on $15M Vaxzevria royalty revenue; cash runway into Q2 2026

Barinthus Biotherapeutics plc.

2024-Q3 EPS reported -$1.04 revenue$14,969,000

Net loss of $8.1M ($0.21/sh) vs $16.9M ($0.43/sh) in Q2; revenue of $15.0M from AstraZeneca Vaxzevria royalty share.
Cash and equivalents $106.1M at Sep 30, 2024, down from $117.8M at Jun 30; cash runway now into Q2 2026.
HBV003 trial of VTP-300 in chronic hepatitis B fully enrolled (121 participants); updated data at AASLD Nov 2024 as late-breaking abstracts.
VTP-1000 Phase 1 AVALON trial in celiac disease initiated; VTP-850 Phase 1 PCA001 trial completed enrollment (22 participants).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.